Legacy Tvardi

Tvardi Therapeutics is a clinical-stage biotechnology company focused on developing breakthrough small molecule inhibitors of STAT3. The company's lead candidate, TTI-101, is an orally bioavailable inhibitor designed to target STAT3, a key protein that drives survival and proliferation in cancer cells and promotes fibrosis. Tvardi is currently evaluating TTI-101 in multiple Phase 2 clinical trials for indications such as hepatocellular carcinoma and idiopathic pulmonary fibrosis. Founded on research from the MD Anderson Cancer Center, the company aims to address significant unmet needs in oncology and chronic inflammatory diseases. Tvardi's approach represents a potential first-in-class therapy for diseases where STAT3 signaling is a primary driver of pathology.